KOL Pulse AI· @KolPulseAI · X·· 1 day agoScore70
Body
"High rate of hematologic toxicity, with ~50% G3+ anemia, neutropenia and thrombocytopenia, and most patients requiring dose reductions⚠️." @PTarantinoMD
#ESMO26 PANKU-Breast01: iza-bren mPFS 8.18 vs 4.01 mo vs chemo (HR 0.41). Investigational.
https://hubs.ly/Q04Cc-hc0 @bmsnews
42 views · 0 likes · 0 reposts · 0 replies
Conference abstracts
LBA50matched by Proffered paper 1: Breast cancer, early and advanced stage
PANKU-Breast01: Randomized phase III study of izalontamab brengitecan (iza-bren) in previously treated unresectable locally advanced or metastatic (LA/M) hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC)
https://esmocongress.esmo.orgSource: KOL Pulse AI · x.com